This news release is available in French.
A signal that promotes insulin secretion and reduces hyperglycemia in a type 2 diabetes animal model is enhanced by the inhibition of a novel enzyme discovered by CHUM Research Centre (CRCHUM) and University of Montreal researchers. The team is part of the Montreal Diabetes Research Center and their study, published recently in Cell Metabolism, was directed by researchers Marc Prentki and Murthy Madiraju.
Insulin is an important hormone in our body that controls glucose and fat utilization. Insufficient insulin release by the beta-cells of the pancreas and interference with the action of insulin lead to type 2 diabetes. The secretion in the blood of insulin is dependent upon the utilization of glucose and fat by the beta-cells and the production of a novel signal that they discovered named monoacylglycerol.
"Despite significant research on the mechanisms implicated in insulin secretion, the signal molecules involved in this process remained enigmatic; the identification of these signals is necessary to develop better therapeutics against diabetes," explains Marc Prentki, Director of the Montreal Diabetes Research Centre and Professor at the University of Montreal. Marc Prentki holds the Canada Research Chair in Diabetes and Metabolism.
"When sugar is being used by the insulin secreting pancreatic beta-cell, it produces monoacylglycerol, a fat-like signal and this is associated with insulin release into blood; we found that the production of monoacylglycerol is essential for glucose-stimulated insulin secretion by the beta-cell," says Murthy Madiraju, Researcher at the CRCHUM.
Importantly, the research team discovered that an enzyme called alpha/beta hydrolase domain-6 (in short ABHD6) breaks down monoacylglycerol and thus negatively controls insulin release. These researchers said that "an ideal drug for type-2 diabetes would increase insulin levels in blood by enhancing the beta cells response to glucose only when it is elevated and also increase the sensitivity of body tissues to insulin; this is precisely what ABHD6 inhibition does and thus we have identified a unique new target for type 2 diabetes."
The research team is currently in the process of discovering new and potent blockers of ABHD6 that do not show any unwanted toxicity and which can be developed as potential drugs for type 2 diabetes. These studies are being done in collaboration with AmorChem Financial, Inc., and its subsidiary NuChem Therapeutics, Montreal.
About the research project
The study was supported by the Canadian Institutes of Health Research. The Montreal research team directed by Marc Prentki and Murthy Madiraju consisted of Shangang Zhao, Yves Mugabo, Jose Iglesias, who are first authors of the study and performed most of the experimental work, and Viviane Delghingaro-Augusto, Roxane Lussier, Marie-Line Peyot, Erik Joly, and Bouchra Taïb, who also contributed. The study was conducted in collaboration with Dr Herbert Gaisano and Li Xie (Toronto), J. Mark Brown and Matthew A. Davis (Winston-Salem, NC), and Abdelkarim Abousalham (France). For more information, please visit the journal page at: http://www.cell.com/cell-metabolism/abstract/S1550-4131(14)00166-1
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.